Just finished an inspiring conversation with Naftali Bennett former prime minister of Israel, and our board member at Remepy, at the growth conference of Calcalist כלכליסט. I am confident that with all the challenges we have recently faced, we have an opportunity to transform and lead many new industries, including pharma, with the new category Remepy is pioneering of Hybrid Drugs. "This is the time to invest in Israel!"
About us
Remepy is Pioneering Hybrid Drugs™. We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
- Website
-
https://www.remepy.com/
External link for Remepy
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Ramat Gan
- Type
- Privately Held
- Founded
- 2022
- Specialties
- Pharma, Biotech, Digital Health, Software, mobile apps, immunology, drug development, oncology, and Neurology
Locations
-
Primary
Get directions
Ramat Gan, IL
-
Get directions
New York, NY, US
Employees at Remepy
Updates
-
Looking forward to hearing the conversation between my partner Michal Tsur and former prime minister of Israel, and Remepy board member Naftali Bennett. Israel is strong, and our secret weapon is entrepreneurship, creativity and resilience! Calcalist כלכליסט Mizrahi-Tefahot Bank בנק מזרחי טפחות Join us on Wednesday at 26/6 at 09:00 AM https://lnkd.in/eDQPmYpa
-
-
Join us today at 6 p.m. for an insightful webinar with Professor Amir Amedi (in Hebrew), organized by the Parkinson’s Association in Israel. During the webinar, Prof. Amedi will explore the latest technologies aimed at enhancing brain connectivity for individuals with Parkinson's disease – including Remepy's groundbreaking Hybrid Drug. Learn more about Remepy's upcoming trial for Parkinson's patients and find out how interested participants can sign up. For the webinar link and details on the trial check the post comments. We hope to see you there! #HybridDrug #DigitalMolecule #Parkinson
-
-
Remepy reposted this
My partner and co-founder Michal Tsur told Forbes why Remepy’s Hybrid Drugs are the next generation of modern medicine, and as Michal put it: “We are using digital tools in order to harness the brain to drive physiological effects that are synergistic with drugs”. Thank you Gil Press for such an interesting and thorough article. Link to the article in comments.
-
-
Remepy reposted this
The Hybrid Drugs that Remepy is developing will transform patient care for many reasons. 1. We will uniquely digitize, scale up and standardize many proven complimentary therapies 2. Will generate consistent real world data that can allow to develop critical digital biomarkers 3. Hybrid drugs are personalized 4. We are using non-invasive interventions to harness the brain to improve drug effects by increasing brain plasticity, triggering the reward system, modulating the immune system and driving behavioral changes. This is made possible because Hybrid drugs combine traditional pharmacological components with non-invasive therapeutic software applications. #precisionmedicine #digitalhealth Or Shoval Amir Amedi Nira Saporta (Rivner) Shahar Shelly M.D Ofer Tur-Sinai Lior Benderski Johnathan Amit Kanarek Sheila Oren, MD MBA Shai Erlich Merav Catalogna, PhD Eran Etam Bar Nathansohn-Levi Dina Kofler Danny Bar-Zohar
-
Remepy reposted this
Just finished sharing Remepy vision for Hybrid Drugs at the #Biomed conference. It was exciting to see here so many friends from 8400 The Health Network Sheila Oren, MD MBA Dorit Sokolov Yair Schindel, MD, MBA Or Shoval Ran Ridnik Ofri Tischler Daphna Murvitz Hilla Ben-Pazi Amir Amedi Shahar Shelly #hybriddrugs #digitalhealth #digitalinnovation
-
-
Remepy reposted this
I'm excited to share that Michal Tsur, my co-founder and co-CEO at Remepy, presented our innovative vision of Hybrid Drugs today at the Biomed Israel 2024 Conference. It’s an exciting step forward for us! 8400 The Health Network
-
-
Looking forward to sharing Remepy's vision for Hybrid Drugs, and to making many new connections at #biomed 8400 The Health Network
-
-
Remepy is looking for a talented Mobile Developer Group Leader with gaming industry experience! A fantastic opportunity to work on an innovative healthcare solution with our amazing team. Know anyone who might be relevant? A full job description is in the first comment. Please share! Johnathan Amit Kanarek Eran Etam Lior Benderski Nira Saporta (Rivner)
-
-
Remepy reposted this
I’m happy to share that Remepy whose board I joined earlier this year has announced today a total of $15M in funding, that will be used to bring to market the first hybrid drug ever. Hybrid drugs are a new type of pharma asset that combines traditional drugs with therapeutic software components, intended to improve the drug effect. I am also excited to share that Danny Bar-Zohar head of R&D and Chief Medical Officer of Merck, will be joining me on Remepy’s board. https://lnkd.in/d33X-i_i Michal Tsur Or Shoval Gigi Levy-Weiss Eric Reiner Yaron Samid 🇮🇱🇺🇸🎗️ Amir Amedi